Wave Life SciencesWVE
Recorded

Wave Life Sciences R&D Day 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration1 hr 44 minParticipants23

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and welcome to Wave's 2026 Research Day. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. Also, as a reminder, this conference is being recorded today. I will now turn the call over to Kate Rausch, Vice President of Corporate Affairs and Investor Relations.

Kate RauschVP of Corporate Affairs and Investor Relations

Good morning, everyone, and welcome to Wave's 2026 Research Day. The slides accompanying today's presentation will be available following the event in the investor section of our website at www.wavelifesciences.com. Before we begin, I would like to remind you that management may make forward-looking statements during today's presentation. These statements are subject to risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in our SEC filings, including our most recent annual report on Form 10-K and our most recent quarterly report on Form 10-Q. We undertake no obligation to update or revise any forward-looking statement for any reason. Today, you will hear from Paul Bolno, our President and Chief Executive Officer, Erik Ingelsson, our Chief Scientific Officer, and Chandra Vargeese, our Chief Technology Officer.

Kate RauschVP of Corporate Affairs and Investor Relations

We are also pleased to welcome Dr. Arun Sanyal, who will share his perspective on PNPLA3 I148M liver disease and the opportunity for an RNA editing correction approach. Following the presentations, our speakers will be available for Q&A, as well as Chris Wright, our CMO. With that, I will turn the presentation over to Paul.

Paul BolnoPresident and CEO

Thanks, Kate. Good morning, and thank you for joining us today. Today marks our eighth annual research day. Each year, we use this time to showcase emerging programs in our pipeline, our platform capabilities, and our recent innovations. As an organization, we are relentlessly focused on our mission of unlocking the broad potential of RNA medicines to transform human health. At Wave, we bring together deep genetic insights and our proprietary chemistry to rapidly advance a pipeline of transformational RNA medicines. There are thousands of known genetically defined diseases, and understanding of how the genetic variations drives disease continues to deepen. At the same time, larger genetic studies and better tools for analyzing big datasets are rapidly expanding the number of strong genetic targets for common diseases. With our multimodal platform, Wave is uniquely positioned to leverage these insights.

Paul BolnoPresident and CEO

For most of the field's history, oligonucleotide innovation has advanced through sugar and backbone modifications. Even today, traditional oligonucleotides are made as a stereorandom mixture with potentially up to 1 million unique isomers in a single dose. Wave's founding premise was to bring rational drug design to oligonucleotides to solve for this, resulting in improved distribution and pharmacologic and safety profiles. With the introduction of controlling backbone stereochemistry, PN chemistry, and modified bases, we've built the foundation for SpiNA-designed siRNAs and pioneered new modalities like RNA editing and bifunctionals. We've demonstrated clinical translation of our proprietary chemistry, RNA editing, allele-selective silencing, and recently, our SpiNA design, further setting us apart in the field and demonstrating the differentiation of our platform. We've been developing a way to extend these innovations beyond the liver, and today, we will provide an update on our PN conjugates.

Paul BolnoPresident and CEO

We have established an Oligonucleotide Center of Excellence for accelerating these innovations into better RNA medicines. The process starts with selecting targets with strong human genetic support. We've built in-house systems to integrate large datasets into our discovery engine. Wave is uniquely situated to have options for choosing the right tool to silence, edit, or upregulate any given target, thereby enabling us to pair the modality that best addresses the target, including the ability to combine multiple modalities together. As you'll hear later, PNPLA3 is a perfect example of where RNA editing enables distinct advantages over siRNA. Using PRISM, we can leverage predictive modeling and rational design to optimize favorable pharmacology and safety profiles for our therapeutics. We've been compounding these learnings for over a decade and continuously improve the platform.

Paul BolnoPresident and CEO

The result is that we develop clinical candidates rapidly at no additional cost to standard oligo development and reproducibly with scalable, cost-effective manufacturing behind them. The most recent example of this process is our WVE-007 INHBE siRNA, which was 18 months from our first in vitro experiment to first human dose. Today, we'll begin in RNA editing and highlight our PNPLA3 program. This program builds on our clinical success with WVE-006 for AATD. PNPLA3 liver disease is a similar story driven by a single base change and with strong human genetic support. We are pleased to be joined today by Dr. Arun Sanyal, who will discuss the unmet need for PNPLA3 I148M patients with liver disease and the opportunity for RNA editing. Erik will then discuss our WVE-008 program, which is advancing towards the clinic.

Paul BolnoPresident and CEO

Chandra will then cover the foundation of our RNAi portfolio and how our SpiNA designs are enabling dramatic improvements in potency and duration of activity, and how they're translating in the clinic with WVE-007 with a safe and well-tolerated profile. Next, she'll speak about how we're using our chemistry to advance PN conjugates to unlock extrahepatic delivery and provide an update on our bifunctional modalities that provide the ability to silence, edit, and/or upregulate two distinct targets with a single construct. Now, joining from The Liver Meeting in Denver, I'm delighted to welcome one of the most influential figures in hepatology, Dr. Arun Sanyal. Dr. Sanyal is a Professor of Medicine and Physiology and Molecular Pathology at VCU, and Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health.

Paul BolnoPresident and CEO

He has chaired the NIH NASH Clinical Research Network, served as president of the American Association for the Study of Liver Diseases, and authored more than 500 publications. He's pioneered diagnostics and therapeutics for fatty liver and end-stage liver disease, and as recently as last week, he was awarded the American Liver Foundation's Leadership Award. Dr. Sanyal will share his perspective on PNPLA3 I148M liver disease and the opportunity for a genetic correction approach. Without further ado, I'll turn the call to Dr. Sanyal.

Arun SanyalProfessor of Medicine and Physiology and Molecular Pathology

Thank you, Paul. May I have the next slide, please? It's a real pleasure for me to give this talk, and we're going to talk today about PNPLA3, specifically a mutation at the 148 position that has been associated with more aggressive disease in the context of first, steatotic liver disease, but now across a whole spectrum of chronic liver diseases. The first identification of PNPLA3 as a potential gene mutation linked to hepatic steatosis came from epidemiological studies with the Dallas Heart Study in 2008. Since then, there have been a number of landmark findings which have provided insight into how this leads to disease, what are its clinical associations, and we are now poised to really talk about how the mutation itself can be modified to change the trajectory of the disease, and that's really going to be the theme of what I'm going to talk about.

Arun SanyalProfessor of Medicine and Physiology and Molecular Pathology

Next slide, please. Beyond linking this gene mutation to having excess fat in the liver, there are now data indicating that if you have this gene mutation, you are much more likely to have cirrhosis. So within cirrhotic populations, this gene mutation is enriched. What is interesting is, it is not just metabolic dysfunction-associated steatotic liver disease, but whether you talk about alcohol-related liver disease, even viral hepatitis, having this gene sets you up for liver trouble if your liver does get into trouble. Next slide, please. What has occurred is that now, with PNPLA3 as the very first sort of gene that was identified, we have a slew of genes that have been linked to steatotic liver disease. But PNPLA3 I148M remains the clearest genotype-defined MASLD target, where whether you look at common polygenic susceptibility variants, it is a central anchor of all of those.

Arun SanyalProfessor of Medicine and Physiology and Molecular Pathology

There are other protective genes that have been identified, and I think this is important that there are gene interactions. The evidence ladder, if you look in the lower right side of this slide, from starting with an association signal, we now know much more about the rare disease burden. We have understanding of disease biology, and we are getting ready to talk about functional and therapeutic validation of this as a target. Next slide, please. The global prevalence of PNPLA3, and this is another way of describing the same mutation, across the world is quite variable, but you can see certain areas where it is particularly overrepresented.

Arun SanyalProfessor of Medicine and Physiology and Molecular Pathology

If you look at Latin America, it is very, very overrepresented, but there are other areas such as China, and here in the U.S., it is estimated we have about 18 million people who have or who carry this gene mutation. Similarly, in Japan and Mexico, many million individuals actually carry this mutation. The public health relevance of today's conversation is underscored by the fact that there are many, many individuals, literally millions, who actually carry this mutation. When you think about the prevalence of steatotic liver disease in a third or more of the general population, and you layer these one on top of the other, that puts a lot of patients at risk from this mutation. Next slide. It is also the strongest genetic risk factor for progressive scarring.

Arun SanyalProfessor of Medicine and Physiology and Molecular Pathology

It is not just cirrhosis, but along the way to cirrhosis, as the liver gets more scarred, PNPLA3, again, across multiple etiologies, has been shown to be a very important genetic driver of accelerated progression of fibrosis and accelerated development of cirrhosis. Once you get there, it is one of the strongest genetic risk factors for the development of hepatocellular carcinoma, which is one of the cancers where we have still not tamed the beast. That creates another opportunity for prevention of hepatocellular carcinoma or to actually flatten that curve. Next slide. If you look at individuals who already have established steatotic liver disease or MASLD, we see first that the impact of the mutation on the likelihood of developing a liver outcome is also age-related, so there is an interaction term with increasing age.

Arun SanyalProfessor of Medicine and Physiology and Molecular Pathology

If you look at our patients who already have advanced fibrosis, they are much older than people who have very early-stage disease, and so this is an important point. On the right-hand side, when you look at the disease allele and the risk of a liver outcome, and these are if you related to having advanced fibrosis, and then you are already seeing the data for the sub-hazard ratio for age over 60. You are seeing that in diabetics, there is an interaction as well. All of these show that while there is a general impact on overall risk of liver outcomes, particularly in older diabetic patients, this is particularly relevant. Again, as you know, with more advanced fibrosis, there is an over-enrichment of people with type 2 diabetes, which has been associated with accelerated disease progression also. Next slide, please. Having this mutation is associated with poorer mortality.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day